The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR also known as fenretinide) is a potent inducer of apoptosis in breast cancer cells. We observed a 4.5-fold reduction in 4-HPR-mediated apoptosis in MCF-7 breast cancer cells transfected with HER2/neu (MCF-7/HER2) as compared with the parental MCF-7 (MCF-7/WT) cells. Blocking HER2/neu with trastuzumab (Herceptin TM ) led to a sixfold increase in 4-HPR-induced apoptosis in HER2/neuoverexpressing cells. These data indicate that HER2/neu reduces the sensitivity of breast cancer cells to 4-HPR. We showed previously that nitric oxide (NO) is essential for 4-HPR to induce apoptosis in breast cancer cells. The inhibitory effects of the 4-HPR and trastuzumab combination correlated with the amount of NO produced in HER2/neu-overexpressing cells. When a NO synthase (NOS) inhibitor was used to block NO production, decreased apoptosis by the 4-HPR and trastuzumab combination was observed. Furthermore, 4-HPRmediated NOSII expression was lower in MCF-7/HER2 than MCF-7/WT cells, but was increased by trastuzumab in HER2/neu-overexpressing cells. Here we report the novel findings that HER2/neu reduces the ability of 4-HPR to induce apoptosis in breast cancer cells, and that one mechanism by which HER2/neu increases the resistance of breast cancer cells to 4-HPR is by decreasing NOSII-mediated NO production.
Introduction
The HER2/neu oncogene is overexpressed in 25-30% of breast cancers and is associated with shorter time to relapse and lower survival rate (Slamon et al., 1987 (Slamon et al., , 1989 , probably because HER2/neu increases breast cancer metastasis (Guy et al., 1992; Tan et al., 1997) and resistance to radiation therapy (Haffty et al., 1996; Burke et al., 1998; Pietras et al., 1999) , chemotherapy (Yu et al., 1996; Baselga et al., 1998; Colomer et al., 2000) , hormonal therapy (Benz et al., 1993; Yu et al., 1996; Burke et al., 1998) , and biological therapy (Hudziak et al., 1989; Benz et al., 1993; Pietras et al., 1994; Tari et al., 2002) . Anti-HER2/neu antibodies, such as trastuzumab (Herceptin TM ), have been used to therapeutically target HER2/neu. Trastuzumab specifically blocks HER2/neu function and expression and has been approved for the treatment of patients with metastatic breast cancer and HER2/neu-overexpressing tumors (Carter et al., 1992; Sliwkowski et al., 1999) .
N-(4-hydroxyphenyl)retinamide (4-HPR also known as fenretinide), a synthetic analogue of all-trans retinoic acid (ATRA), induces apoptosis in breast cancer cells in vitro (Sheikh et al., 1995; Fanjul et al., 1996; Wang and Phang, 1996; Herbert et al., 1999) . 4-HPR inhibits carcinogen-induced mammary cancer in animal models (Moon et al., 1979) . Furthermore, 4-HPR preferentially accumulates in breast tissue, and this may account for its reduced toxicity compared with other retinoids (Costa et al., 1989; Mehta et al., 1991; Formelli et al., 1993) . Clinically, 4-HPR has shown great promise as a breast cancer chemopreventive agent; 4-HPR appears to be effective in reducing local recurrent and contralateral breast cancer in premenopausal women (Veronesi et al., 1999; Decensi et al., 2000) . However, the use of 4-HPR in patients with advanced breast cancer has shown limited success (Modiano et al., 1990) . Various agents are currently being used to improve the clinical efficacy of 4-HPR in breast cancer chemoprevention and treatment.
The mechanisms by which 4-HPR exerts its apoptotic effects are not clear. Unlike ATRA, 4-HPR induces its apoptotic effects mainly via retinoid receptor-independent mechanisms (Sheikh et al., 1995; Fanjul et al., 1996; Kazmi et al., 1996) . We have recently reported that the production of nitric oxide (NO) is vital for 4-HPR to induce apoptosis in breast cancer cells (Simeone et al., 2002) . NO is a free radical synthesized from arginine by three different isoforms of nitric oxide synthase (NOS). We have found that 4-HPR induces NO production in breast cancer cells by increasing the expression of both NOSII and NOSIII isoforms (Simeone et al., 2002) . We also observed that the ability of 4-HPR to induce NO production and apoptosis was greater in estrogen receptor-positive (ER þ ) breast cancer cells than in estrogen receptor-negative (ERÀ) breast cancer cells (Simeone et al., 2002) . HER2/neu is highly expressed in ERÀ breast cancer cells (Tandon et al., 1989; Wright et al., 1989) . In fact, the ERÀ cells used in our initial experiments, MDA-MB-453 and SKBr-3, are known HER2/neu-overexpressing cell lines (Tari et al., 1999) . This led us to speculate that HER2/neu may reduce the ability of 4-HPR to induce apoptosis by suppressing 4-HPR-induced NO production. Here we report that HER2/neu decreased 4-HPR-mediated apoptosis, NO-SII expression, and NO production, whereas inhibition of HER2/neu by trastuzumab increased 4-HPR-induced apoptosis, NOSII expression and NO production. Inhibition of NO production suppressed the enhancement of 4-HPR-induced apoptosis by trastuzumab. Thus, we have identified one mechanism by which HER2/neu reduces the sensitivity of breast cancer cells to 4-HPR, that is, by decreasing NOSII expression to suppress NO production.
Results

HER2/neu suppressed 4-HPR-induced apoptosis and NO production in breast cancer cells
To determine whether HER2/neu suppresses 4-HPR's induction of apoptosis and NO production, the ability of 4-HPR to induce apoptosis and NO production in parental MCF-7 (MCF-7/WT) cells was compared with that in MCF-7 cells transfected with HER2/neu (MCF-7/HER2). We elected to use 1 and 2.5 mm 4-HPR because these doses are clinically achievable (Formelli et al., 1993) . We chose MCF-7 cells because we have previously demonstrated that these cells are sensitive to 4-HPR-mediated apoptosis and NO production (Simeone et al., 2002) and have very low levels of HER2/ neu (Figure 1 ). 4-HPR treatment of MCF-7/WT cells increased the proportion of apoptotic cells in a dosedependent manner as shown by the rise in the sub-G1 peak in the flow cytometric analysis (Figure 2 ). At 1 and 2.5 mm 4-HPR, the percentages of apoptotic cells increased from 3.4 to 18.3 and 58.2%, respectively. In contrast, the 1 mm dose of 4-HPR did not induce apoptosis in MCF-7/HER2 cells. The proportion of apoptotic cells increased from 3.8 to 12.6% in MCF-7/ HER2 cells treated with 2.5 mm 4-HPR; however, this increase was much lower than was observed for MCF-7/ WT cells (Figure 2 ). NO production was increased in a dose-dependent manner in both cell types; however, (Figure 2 ). NO production was threefold higher (Po0.001) in MCF-7/WT cells than in MCF-7/HER2 cells at the 2.5 mm concentration of 4-HPR. 4-HPR-mediated apoptosis was directly correlated with NO generation. These data indicate that overexpression of HER2/neu impairs NO generation and apoptosis in 4-HPR-treated breast cancer cells.
Trastuzumab increased 4-HPR-mediated apoptosis and NO production in HER2/neu-overexpressing breast cancer cells
Trastuzumab was used to block the function of HER2/ neu to determine whether this blocking would increase the apoptotic effects of 4-HPR in MCF-7/HER2 and BT474 breast cancer cells. These two cell lines were used because their sensitivity towards trastuzumab is different; MCF-7/HER2 cells are less sensitive to trastuzumab than BT474 cells Sliwkowski et al., 1999; Lu et al., 2001) . MCF-7/HER2 and BT474 cells were treated with 4-HPR alone or in combination with trastuzumab. Trastuzumab alone at the concentrations used did not affect apoptosis in MCF-7/HER2 (Figure 2 ) or BT474 cells (Figure 4 ). Trastuzumab enhanced 4-HPR-mediated apoptosis in both cell lines. In MCF-7/ HER2 cells, the proportion of apoptotic cells was increased from 12.6 to 18.2% when trastuzumab was combined with the 2.5 mm dose of 4-HPR (Figure 2 ). The proportion of apoptotic cells was increased from 3.5 to 21.6% when trastuzumab was combined with the 1 mm dose of 4-HPR in BT474 (Figure 4 ) cells.
We then determined whether trastuzumab would increase 4-HPR-induced NO production. Trastuzumab alone slightly increased NO production in all HER2/ neu-overexpressing cell lines (Figure 3 ). Treatment with 4-HPR alone resulted in a dose-dependent increase in NO production in all cell lines tested. The addition of trastuzumab enhanced 4-HPR-induced NO production in all cells tested (Figure 3 ). In MCF-7/HER2 and MDA-MB-453 cells, a synergistic effect and an additive effect (Po0.05) were observed, respectively, when trastuzumab was combined with the 2.5 mm dose of 4-HPR. In BT474 cells, a synergistic effect (Po0.05) was obtained when trastuzumab was combined with the 1 mm dose of 4-HPR, and an additive effect (Po0.05) was obtained when trastuzumab was combined with the 2.5 mm dose of 4-HPR. A synergistic effect (Po0.05) of 4-HPR and trastuzumab on NO production was observed in SKBr-3 cells at both doses of 4-HPR. These findings further support the theory that overexpression of HER2/neu can reduce 4-HPR-induced apoptosis and NO production in breast cancer cells. , 1 Â 10 5 , and 1.5 Â 10 5 cells/well, respectively, in six-well plates in DMEM/F12 medium supplemented with 5% FBS. Cells were treated with 4-HPR (1, 2.5 mm) in the absence and presence of trastuzumab for 5 days. NO production was determined by measuring its stable end product nitrite using a colorimetric nonenzymatic nitric oxide assay kit. Nitrite values were normalized to cell number. Each experimental treatment was performed in triplicate; values shown are means7s.d.
* Synergistic effects; þ , additive effects (Po0.05)
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Inhibition of NO production suppressed apoptosis induced by 4-HPR in HER2/neu-overexpressing breast cancer cells
To determine the importance of suppressed NO production in the increased resistance of HER2/neuoverexpressing cells to 4-HPR, we used the competitive NOS inhibitor S,S 0 -1,3-phenylene-bis(1,2-ethanediyl)-bis-isothiourea dihydrobromide (1,3-PBITU) to inhibit NO production. MCF-7/HER2 cells were treated with 4-HPR (2.5 mm) in the presence and absence of 1,3-PBITU. 1,3-PBITU at the concentrations used (1, 5 mm) was not cytotoxic to these cells. 1,3-PBITU effectively suppressed 4-HPR-induced NO production in a dosedependent manner (Table 1a) . Suppression of NO production desensitized MCF-7/HER2 cells to the inhibitory effects of 4-HPR (Table 1a) . Cell counts of MCF-7/HER2 cells treated with 4-HPR and 1,3-PBITU were statistically higher (Po0.05) than those of cells treated with 4-HPR alone.
BT474 cells were also treated with 4-HPR (1 mm) in the presence and absence of 1,3-PBITU. 1,3-PBITU was 
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A-M Simeone et al not cytotoxic to these cells at doses up to 10 mm (Table 1b) . 4-HPR alone slightly increased NO production and growth inhibition. Inhibition of NO production overcame the 4-HPR inhibitory effects in BT474 cells (Table 1b) . The 1 and 10 mm doses of 1,3-PBITU restored the cell counts of 4-HPR-treated BT474 cells to those of untreated cells. Trastuzumab increased 4-HPR-induced growth inhibition and NO production. However, 1,3-PBITU effectively suppressed the NO production induced by 4-HPR and trastuzumab in a dose-dependent manner (Table 1b) . Inhibition of NO production suppressed trastuzumab's enhancement of 4-HPR-induced growth inhibition (Table 1b) . Compared with 4-HPR and trastuzumab, the addition of 1,3-PBITU significantly (Po0.05) increased cell counts (Table 1b) . Cell counts of cells treated with 4-HPR and trastuzumab in the presence of 10 mm 1,3-PBITU were not statistically different (P40.05) from counts for untreated cells. Inhibition of NO production also suppressed trastuzumab's enhancement of 4-HPRmediated apoptosis (Figure 4 ). The percentage of apoptotic cells was decreased from 26.2 to 6.7% when 1,3-PBITU was added to the 4-HPR plus trastuzumab combination (Figure 4) . Thus, NO is essential for the induction of apoptosis by 4-HPR, whether alone or in combination with trastuzumab, in HER2/neu-overexpressing breast cancer cells.
HER2/neu suppressed 4-HPR-mediated NO production by suppressing NOSII expression in breast cancer cells
We have previously shown that 4-HPR increases the expression of NOSII and NOSIII in breast cancer cells (Simeone et al., 2002) . Since HER2/neu suppressed 4-HPR's induction of NO, we wanted to determine which NOS isoforms were affected by HER2/neu. MCF-7/WT and MCF-7/HER2 cells were treated with 4-HPR alone (2.5 mm) and subjected to immunohistochemical staining for NOSII and NOSIII. The intensity and percentage of NOSII and NOSIII immunostainings are presented in 
Trastuzumab increased 4-HPR-induced NOSII expression in HER2/neu-overexpressing breast cancer cells
To determine whether blocking HER2/neu would restore 4-HPR-induced NOSII expression, BT474 cells were treated with 4-HPR (1 mm) in the absence and presence of trastuzumab. 
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Discussion
Here we report that HER2/neu suppresses 4-HPRmediated apoptosis in breast cancer cells predominantly by suppressing NOSII expression and NO production.
In agreement with these results, Rao et al. (2000) reported that 4-HPR was unable to decrease the mammary tumor incidence and average tumor weight in transgenic mice bearing c-neu. However, Jinno et al. (1999) reported that 4-HPR was able to induce apoptosis in the preneoplastic human mammary epithelial 184-B5/HER cell line bearing high levels of HER2/ neu. This discrepancy may be due to their use of an immortalized, nontumorigenic mammary epithelial cell line, whereas we used breast tumorigenic cell lines. High concentrations of NO, as induced by NOSII, are cytotoxic (Li et al., 1991) , can prevent murine tumors from metastasizing (Dong et al., 1994; Xie et al., 1995) , inhibit proliferation, and induce apoptosis in breast cancer cells (Adami et al., 1998; Reveneau et al., 1999; Umansky et al., 2000) . The endogenous expression of NOSII within breast tumor cells has been inversely correlated to the tumor's metastatic potential and may have an inhibitory role on breast cancer metastasis (Tschugguel et al., 1999) . On the other hand, high expression of NOSII within the stromal cells of breast tumors (Thomsen et al., 1995; Vakkala et al., 2000) or within tumors X2 cm (Duenas-Gonzalez et al., 1997) has been correlated with breast cancer metastasis, possibly because of its association with higher vascular density and increased angiogenesis (Vakkala et al., 2000) . Breast cancer patients with HER2/neu-overexpressing tumors are resistant to a variety of cancer therapies (Hudziak et al., 1989; Benz et al., 1993; Pietras et al., 1994; Yu et al., 1996; Baselga et al., 1998; Tari et al., 2002) . We previously demonstrated that HER2/neu induces ATRA resistance . ATRA has been found to increase NO production in a breast cancer cell line (Martin et al., 2000) ; therefore, we determined whether HER2/neu suppresses ATRA-induced NO production. We found that HER2/neu blocked NOSIImediated NO production induced by ATRA (data not shown), but ATRA with or without trastuzumab was less potent than 4-HPR with or without trastuzumab in inducing NO production. Unlike 4-HPR, ATRA uses retinoid receptor-dependent mechanisms to arrest cell growth at the G1 phase (Mangelsdorf et al., 1994; Wilcken et al., 1996; Toma et al., 1997 Toma et al., , 1998 Mangiarotti et al., 1998) . Therefore, it is surprising that HER2/neu could suppress the production of NO by these two different retinoid analogues. It remains to be determined whether HER2/neu-induced suppression of NO in breast cancer is a mechanism specific to retinoids or whether it has a broader effect on chemotherapy and hormone resistance. This is particularly important, as NO production has been linked to apoptosis induction by chemotherapeutic and biological agents, including doxorubicin (Kalivendi et al., 2001 ) and tumor necrosis factor-a (Binder et al., 1999) . Future studies will be conducted to determine the mechanisms involved in the HER2/neu-mediated suppression of 4-HPR-induced NOSII expression and NO production in breast cancer cells.
Anti-HER2/neu antibodies such as trastuzumab represent a significant development in the treatment of HER2/neu-positive breast cancer. However, the use of trastuzumab is limited by low response rates (11-26%; Cobleigh et al., 1999; Vogel et al., 2002) and the development of drug resistance within 12 months (Slamon et al., 2001) . Therefore, trastuzumab has been combined with paclitaxel (Seidman et al., 2001; Slamon et al., 2001) , cisplatin (Pegram et al., 1998) , docetaxel , and vinorelbine (Burstein et al., 2001) to improve its potency. In the present study, the 4-HPR plus trastuzumab combination resulted in additive and synergistic effects on apoptosis and NO production in HER2/neu-overexpressing cells. The well-documented long-term tolerability and chemopreventive properties of 4-HPR make it an extremely advantageous agent to be used in combination therapies (Veronesi et al., 1999; Decensi et al., 2000) . Pharmacologically achievable doses of 4-HPR and trastuzumab were utilized in the present study (Formelli et al., 1993; Witters et al., 1997) ; therefore, combining 4-HPR with trastuzumab may represent a novel chemopreventive and therapeutic strategy that should benefit patients with these very hard-to-treat breast cancers.
Materials and methods
Reagents
Trastuzumab was kindly provided by Genentech (San Francisco, CA, USA). 4-HPR, ATRA, Triton X-100, and b-actin monoclonal antibody were purchased from Sigma Chemical Co. (St Louis, MO, USA). HER2/neu monoclonal antibody was purchased from Oncogene (Boston, MA, USA). NOSII and NOSIII antibodies were purchased from BD Transduction Laboratories (San Diego, CA, USA). Vectastain Elite ABC (avidin-biotin-peroxidase complex) kit, hematoxylin, and 3-amino-9-ethyl-carbazole (AEC) were purchased from Vector Laboratories (Burlingame, CA, USA). AquaMount was purchased from Lerner Laboratories (Pittsburgh, PA, USA). Stock solutions (10 mm) of 4-HPR and ATRA were prepared in dimethyl sulfoxide and stored at À201C. 1,3-PBITU was purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). Stock solutions (10 mm) of 1,3-PBITU were prepared in water and stored at À201C. All reagents were diluted in culture medium to the indicated final concentration.
Cell lines and culture conditions
MCF-7/WT cells and the HER2/neu-overexpressing breast cancer cell lines MDA-MB-453, BT474, and SKBr-3 were obtained from American Type Cell Culture (Manassas, VA, USA). MCF-7 cells transfected with the HER2/neu gene were kindly provided by Dr Mien-Chie Hung (Houston, TX, USA). Cells were cultured in Dulbecco's modified Eagle medium (DMEM)/F12 medium supplemented with 5% heat-inactivated fetal bovine serum (FBS) at 371C under 5% CO 2 in a humidified incubator. MCF-7/HER2 cells were cultured in DMEM/F12 medium supplemented with 5% FBS and the antibiotic G418 (500 mg/ml).
Western blot
Protein lysates (50 mg) from untreated exponentially growing MCF-7/WT, MCF-7/HER2, MDA-MB-453, SKBr-3, and BT474 cells were loaded onto a 10% polyacrylamide gel to determine HER2/neu status of these breast cancer cell lines. Proteins were electrophoresed and electrotransferred as described by Simeone et al. (2002) . Membranes were incubated with the appropriate primary and secondary antibodies. Protein bands were visualized by enhanced chemiluminescence (Kirkegard and Perry Laboratories, Gaithersburg, MD, USA). b-Actin was used as a loading control. Images were scanned using an Alpha Innotech Densitometer (Alpha Innotech, San Leadro, CA, USA). , and 1.5 Â 10 5 cells/well, respectively, in six-well plates in 2 ml of DMEM/F12 medium supplemented with 5% FBS. After 24 h, cells were treated. MCF-7/WT and MCF-7/ HER2 cells were treated with 4-HPR alone (1, 2.5 mm). MCF-7/HER2, MDA-MB-453, BT474, and SKBr-3 cells were treated with either 4-HPR alone (1, 2.5 mm) or 4-HPR in combination with trastuzumab. Trastuzumab was used at a dose of 1.0 mm for MCF-7/HER2 and MDA-MB-453 cells and at a dose of 0.1 mm for SKBr-3 and BT474 cells. After 5 days of incubation, cell growth was determined by total live cell counts using trypan blue exclusion. Supernatants were collected from treated cells, and aliquots were stored at À801C for NO determination. Total NO was determined by quantifying nitrite, the stable end product of NO oxidation. Nitrite accumulation was determined spectrophotometrically using a colorimetric nonenzymatic nitric oxide assay kit (Oxford Biomedical Research, Oxford, MI, USA). Briefly, 100-ml samples were incubated with 0.5 g of cadmium beads overnight. Cadmium was used to catalyze the reduction of nitrate to nitrite, thus allowing for the measurement of total NO present in the samples. The samples were reacted with an equal volume of Greiss reagent (1% sulfanilamide and 0.1% naphthylethylenediamine), and the absorbance was measured at 540 nm in a microplate reader. Sodium nitrite was used as a standard. Nitrite values were normalized for total cell counts and expressed as mm per 1 million cells. The values reported are the means (7s.d.) of experiments performed in triplicate.
Apoptosis analysis
The effect of 4-HPR alone or in combination with trastuzumab on apoptosis was analysed by flow cytometry. MCF-7/ WT and MCF-7/HER2 cells were plated at 1 Â 10 5 cells/well in 2 ml of DMEM/F12 medium supplemented with 5% FBS. After 24 h, cells were treated with 4-HPR (1, 2.5 mm). MCF-7/ HER2 cells were also treated with trastuzumab alone (1.0 mm) or 4-HPR (2.5 mm) plus trastuzumab. BT474 cells were plated at 1.5 Â 10 5 cells/well in 2 ml of DMEM/F12 medium supplemented with 5% FBS. The next day, cells were treated with 4-HPR alone (1 mm) or in combination with trastuzumab (0.1 mm). After 5 days of incubation, cells were harvested and prepared for flow cytometry. Approximately 1 Â 10 6 cells were trypsinized, collected by centrifugation at 1500 r.p.m. for 5 min, washed in phosphate-buffered saline (PBS), and resuspended in 1 ml of PBS. The cell suspension was added to 1 ml of cold 70% ethanol and incubated overnight at À201C. Cells were then centrifuged at 1500 r.p.m. for 10 min at 41C and washed twice in PBS, and the pellet was left loose. Approximately 0.5-1 ml of PBS containing RNase (20 mg/ml) and propidium iodide (50 mg/ml) was added to each pellet followed by a 20-min incubation at room temperature. Flow cytometric analysis was performed using a Coulter Epics profile 488 laser.
Inhibition of NO production
The NOS inhibitor 1,3-PBITU was used to block NO synthesis. MCF-7/HER2 and BT474 cells were plated at 1 Â 10 5 and 1.5 Â 10 5 cells/well, respectively, in six-well plates in 2 ml of DMEM/F12 medium supplemented with 5% FBS. The next day, MCF-7/HER2 cells were treated with 4-HPR alone (2.5 mm) in the presence and absence of 1,3-PBITU (1, 5 mm). BT474 cells were treated with 4-HPR alone (1 mm) or in combination with trastuzumab in the absence and presence of PBITU (1, 10 mm) for 5 days. After incubation, cell growth, apoptosis, and NO production were determined as described above.
Immunohistochemistry MCF-7/WT and MCF-7/HER2 cells were plated at 1 Â 10 5 cells/well in six-well plates in DMEM/F12 medium supplemented with 5% FBS and treated with 4-HPR (2.5 mm) for 3 days. BT474 cells were plated at 1.5 Â 10 5 cells/well in six-well plates in DMEM/F12 medium supplemented with 5% FBS. Cells were treated with 4-HPR (1 mm) in the absence and presence of trastuzumab (0.1 mm) for 4 days. After the appropriate incubation period, cells were harvested and suspended at 1 Â 10 6 cells/ml in PBS. Cytospins for each treatment were prepared by using 100 ml of the appropriate cell suspension. Slides were quick-fixed in À201C acetone and stored at À201C until immunostaining. Slides were prepared according to the protocol of Simeone et al. (2002) . Briefly, slides were fixed in acetone at À201C and then incubated in 3% hydrogen peroxide in methanol to block endogenous peroxidase activity. The slides were incubated in PBS containing 0.05% Triton X-100 to permeabilize the cells. The Vectastain Elite ABC kit was then used to detect primary antibody staining. The immunostaining was developed using AEC as a chromagen. Slides were counterstained with hematoxylin and mounted with Aqua-Mount. The slides were analysed for both percentage and intensity of immunolabeling. The intensity of NOS immunostainings was evaluated by dividing the cytoplasmic staining reaction into four groups: À, none; þ , light; þ þ , moderate; and þ þ þ , intense. The actual percentages of cells positive for NOS staining were determined.
Statistical analysis
Statistical analysis of NO production induced in MCF-7/WT and MCF-7/HER2 cells was performed using a two-tailed paired t-test. For statistical analysis of the NOS inhibitor experiments, the Shapiro-Wilk test was first performed to assess the normality assumption of the data sets obtained from the MCF-7/HER2 and BT474 cell lines. The data were normally distributed, and therefore two-sample t-tests were performed to compare cell counts between treatments for each cell line. For the MCF-7/HER2 cell line, using the two-sample t-test, the 2.5 mm 4-HPR þ 1 mm 1,3-PBITU group and the 2.5 mm 4-HPR þ 5 mm 1,3-PBITU group were compared with the group of untreated cells as well as the group treated with 2.5 mm 4-HPR alone. Cell counts of untreated cells were compared with counts for each of the six treatment groups within the BT474 cell line, namely 1 mm 4-HPR alone, 4-HPR þ 1 mm 1,3-PBITU, 4ÀHPR þ 10 mm 1,3-PBITU, 4-HPR þ trastuzumab, 4-HPR þ trastuzumab þ 1 mm 1,3-PBI-TU, and 4-HPR þ trastuzumab þ 10 mm 1,3-PBITU. In addition, a t-test was performed to compare 4-HPR alone with the two groups with 1,3-PBITU. Similarly, a t-test was used to compare the group with 4-HPR þ trastuzumab with the two groups with 1,3-PBITU. The significance level for each individual comparison (0.00417) was adjusted by the Bonferroni method to account for multiple testing. All analyses were performed using SAS statistical software at an overall significance level of 0.05.
Synergy was tested using a two-sample, one-tailed t-test between two populations. The first population is the one with the mean equal to the average NO production when 4-HPR and trastuzumab are present. The second population is the one in which the mean is the sum of the average NO production from 4-HPR and the average NO production from trastuzumab. The null hypothesis is that the mean NO production of the joint application of the two agents is less than (subadditive) or equal to (additive) the sum of the mean NO production of one agent and the mean NO production of the other agent.
The alternative hypothesis is that the mean NO production of the joint application of the two agents is greater than the sum of the mean NO production of the two agents separately. If Po0.05, the null hypothesis is rejected and a significant synergy is found. If PX0.05, the null hypothesis is not rejected, and either there is a subadditive mean NO production or the average NO production of the joint application is equal (additive) to the sum of NO productions of the two agents separately.
